VERIQA RT EPID 3D
Pre-Treatment and In Vivo 3D EPID Dosimetry with Monte Carlo Calculations: VERIQA RT EPID 3D is part of the VERIQA platform for integrated, independent patient QA.
It combines phantomless pre-treatment and in vivo EPID dosimetry in a fully automated solution, enabling true 3D patient dose reconstruction in the patient anatomy for all treatment sites.
Safer treatments, faster.
What makes VERIQA RT EPID 3D so powerful? Watch the video.
10 Reasons Why You Should Use VERIQA RT EPID 3D for Treatment Plan and Delivery Verification
Advanced 3D Back-Projection Approach
With a unique, patent-pending Monte Carlo-based inhomogeneity correction
VERIQA RT EPID 3D builds on the well-established back-projection algorithm developed by the NKI-AVL, and adds a unique, patent-pending Monte Carlo-based inhomogeneity correction. It allows accurate patient dose reconstruction for all treatment sites, including those with significant tissue heterogeneities.

Fully Automated Workflow - from Image Acquisition to Documentation
Featured article: Reimaging patient QA with Monte Carlo calculations
VERIQA RT EPID 3D ensures true 3D dose verification for both pre-treatment and in vivo EPID dosimetry. Check out the featured article published on Physicsworld to learn more about the algorithm and the clinical benefits of using automated 3D EPID dosimetry as an efficient tool for patient-specific QA. Find out how Monte Carlo comes into play and why you should use VERIQA RT EPID 3D to ensure safer treatments.

In vivo 3D EPID dosimetry
Identify patient-related errors, which occur over the course of treatment
RT EPID 3D uses the same algorithm for both pre-treatment and in vivo verification, allowing you to compare in vivo dose with pre-treatment dose for each delivered fraction. This makes it much easier for you to detect patient-related errors, such as anatomical changes and/or setup issues, which are specific to each fraction, and to better estimate their dosimetric impact.
In the figure on the left, it can be seen how the difference between in vivo and pre-treatment (virtual) patient results becomes larger as the changes in lung density increase. After the result of the 3rd in vivo verification the radiation oncologist was consulted.
Source: Olaciregui-Ruiz et al, Phys Med. 2017 May;37:49-57, doi: 10.1016/j.ejmp.2017.04.016
Selected Publications
Mans et al. Reduction of systematic dosimetric uncertainties in volumetric modulated arc therapy triggered by patient-specific quality assurance phiRO, volume 21, P6-10, January 2022
Olaciregui-Ruiz et al. Extending in aqua portal dosimetry with dose inhomogeneity conversion maps for accurate patient dose reconstruction in external beam radiotherapy. Phys Imaging Radiat Oncol. 2022 Apr 14;22:20-27
Olaciregui-Ruiz et al. Transit and non-transit 3D EPID dosimetry versus detector arrays for patient specific QA. J Appl Clin Med Phys, 1-12 (2019)
Olaciregui-Ruiz et al. Site-specific alert criteria to detect patient-related errors with 3D EPID transit dosimetry. Med Phys 46, 45-55 (2019)
Olaciregui-Ruiz et al. Virtual patient 3D dose reconstruction using in air EPID measurements and a back-projection algorithm for IMRT and VMAT treatments. Phys Med 37, 49-57 (2017)
Mijnheer et al. Overview of 3-year experience with large-scale electronic portal imaging device-based 3-dimensional transit dosimetry. Pract Radiat Oncol 5, e679-e687 (2015)
Mans et al. 3D Dosimetric verification of volumetric-modulated arc therapy by portal dosimetry. Radiother Oncol 94, 181-187 (2010)
Wendling et al. A simple backprojection algorithm for 3D in vivo EPID dosimetry of IMRT treatments. Med Phys 36, 3310-3321 (2009)
Wendling et al. Accurate two-dimensional IMRT verification using a back-projection EPID dosimetry method. Med Phys 33, 259- 273 (2006)